⌕
Candel Therapeutics · CADL · Nasdaq
Tenet 45 · Mixed
Compare
$5.80−6.53%At closeTenet 45 · Mixed
$5.80−0.41 (−6.53%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Candel Therapeutics (CADL) Stock

Candel Therapeutics (CADL) closed at $5.80 on Nov 16, 2026; its Tenet Score is 45 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$5.80
Nov 16, 2026
Market cap
$454.6M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
4.35 – 14.00
low → high
Tenet Score
45/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Candel Therapeutics Inc scores 45/100. Mixed. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 45 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
45/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
55
Quality
16
Health
65
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueCQualityFHealthCGrowth—MomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
3.7×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−94%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
7.57
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Candel Therapeutics Inc

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 44 US ETFs · top wrappers by weightSee all ETFs holding CADL →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Candel Therapeutics in?

Candel Therapeutics is in the Healthcare sector and the Drugs industry.

What is Candel Therapeutics' Tenet Score?

Candel Therapeutics' Tenet Score is 45 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.